Literature DB >> 9622136

Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture.

D Bani1, P Failli, M G Bello, C Thiemermann, T Bani Sacchi, M Bigazzi, E Masini.   

Abstract

The peptide hormone relaxin (RLX) has been shown to elicit a powerful vasodilatory response in several target organs. This response is mediated by the stimulation of intrinsic nitric oxide (NO) generation. The present study was designed to clarify whether RLX directly promotes the relaxation of vascular smooth muscle cells through stimulation of NO generation. Vascular smooth muscle cells from bovine aortas were incubated with RLX at concentrations ranging from 1 nmol/L to 1 micromol/L. The expression and activity of NO synthase, production of NO, and the intracellular levels of cGMP and Ca2+ were determined. The cell morphology and signal transduction mechanisms of these bovine aortic smooth muscle cells in response to RLX were also studied. RLX stimulated the expression of immunoreactive inducible NO synthase and increased significantly and in a concentration-related fashion inducible NO synthase activity, NO generation, and intracellular cGMP levels. Concurrently, RLX significantly decreased cytosolic Ca2+ concentrations and caused changes in cell shape and the actin cytoskeleton that were consistent with cell relaxation. The signal transduction mechanisms leading to the enhanced expression of inducible NO synthase protein and activity caused by RLX involve the activation of tyrosine kinase, phosphatidylcholine-phospholipase C, and the transcription factor nuclear factor-kappaB, similar to bacterial endotoxins and proinflammatory cytokines. This study suggests that RLX is an endogenous agent capable of regulating vascular tone by activation of the L-arginine-NO pathway in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622136     DOI: 10.1161/01.hyp.31.6.1240

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  30 in total

1.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

Authors:  E Masini; G Zagli; J F Ndisang; M Solazzo; P F Mannaioni; D Bani
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

3.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

4.  Stabilization of cGMP-dependent protein kinase G (PKG) expression in vascular smooth muscle cells: contribution of 3'UTR of its mRNA.

Authors:  Hassan Sellak; Thomas M Lincoln; Chung-Sik Choi
Journal:  J Biochem       Date:  2011-02-03       Impact factor: 3.387

5.  Relaxin regulates myofibroblast contractility and protects against lung fibrosis.

Authors:  Xiangwei Huang; Ying Gai; Naiheng Yang; Baogen Lu; Chrishan S Samuel; Victor J Thannickal; Yong Zhou
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

6.  Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow.

Authors:  Lenka A Vodstrcil; Marianne Tare; Jacqueline Novak; Nicoleta Dragomir; Rolando J Ramirez; Mary E Wlodek; Kirk P Conrad; Laura J Parry
Journal:  FASEB J       Date:  2012-06-28       Impact factor: 5.191

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

8.  Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

Review 9.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

10.  Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats.

Authors:  Vanessa M Ferreira; Thiago S Gomes; Luciana A Reis; Alice T Ferreira; Clara V Razvickas; Nestor Schor; Mirian A Boim
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.